Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-06940434 |
Synonyms | |
Therapy Description |
PF-06940434 is an integrin alpha v beta 8 antagonist that prevents the activation of TGFB1, leading to an anti-tumor response (Mar 2020). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-06940434 | PF06940434|PF 06940434 | PF-06940434 is an integrin alpha v beta 8 antagonist that prevents the activation of TGFB1, leading to an anti-tumor response (Mar 2020). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Active, not recruiting | USA | SVK | AUS | 2 |